StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Alnylam Pharma (ALNY) to Discontinue Development of Revusiran; Decision Will Not Affect Patisiran
October 5, 2016 4:31 PM
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced that upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Hot FDA News
Management Comments
Trading Halts
Next Articles
Morgan Stanley Downgrades Alnylam Pharmaceuticals (ALNY) to Equalweight
October 7, 2016 6:32 AM
Alnylam Pharmaceuticals (ALNY) PT Cut to $77 at Chardan
October 6, 2016 7:39 AM
Alnylam (ALNY) PT Cut to $137 at Needham & Company; Long-Term Investors Should Buy Weakness
October 6, 2016 7:26 AM
Credit Suisse Cuts Alnylam (ALNY) PT to $50, Keeps 'Outperform'
October 6, 2016 7:23 AM
Alnylam (ALNY) PT Cut to $58 at Jefferies
October 6, 2016 6:47 AM
Jefferies Sees No Read-Through to The Medicines Company (MDCO) PCSK9 from Alnylam Setback
October 6, 2016 6:44 AM
JPMorgan Downgrades Alnylam Pharmaceuticals (ALNY) to Neutral
October 6, 2016 6:41 AM
Barclays Downgrades Alnylam Pharmaceuticals (ALNY) to Equalweight
October 6, 2016 6:41 AM
Leerink Partners Downgrades Alnylam Pharmaceuticals (ALNY) to Market Perform
October 6, 2016 6:39 AM
Medicines Co. (MDCO) Sells-Off with Alnylam (ALNY) Despite Providing Update
October 5, 2016 5:54 PM
Alnylam Pharmaceuticals Discontinues Revusiran Development
October 5, 2016 4:30 PM
Alnylam Pharma (ALNY) trading halted with news pending
October 5, 2016 4:25 PM
Alnylam Commemorates 10th Anniversary of the Nobel Prize in Physiology or Medicine Awarded for the Discovery of RNAi
October 3, 2016 9:00 AM
